DARE ▼ -1.4% - Daré Bioscience, Inc. $DARE - Daré Bioscience Announces Peer-Reviewed Publication of Phase 1 Sildenafil Cream Study in Men Demonstrating Substantially Lower Systemic Exposure Versus Oral Sildenafil Daré Bioscience shares declined 1.4% following the announcement of a peer-reviewed publication showing that its sildenafil cream formulation achieved substantially lower systemic exposure compared to oral sildenafil in a Phase 1 study in men. The lower systemic absorption profile could reduce safety concerns and side effects associated with oral formulations, potentially differentiating the product in the market. 14-SEP-2026 08:50 AM ET